Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.
Ontology highlight
ABSTRACT: Insufficient pancreatic β-cell mass or function results in diabetes mellitus. While significant progress has been made in regulating insulin secretion from β-cells in diabetic patients, no pharmacological agents have been described that increase β-cell replication in humans. Here we report aminopyrazine compounds that stimulate robust β-cell proliferation in adult primary islets, most likely as a result of combined inhibition of DYRK1A and GSK3B. Aminopyrazine-treated human islets retain functionality in vitro and after transplantation into diabetic mice. Oral dosing of these compounds in diabetic mice induces β-cell proliferation, increases β-cell mass and insulin content, and improves glycaemic control. Biochemical, genetic and cell biology data point to Dyrk1a as the key molecular targe
SUBMITTER: Shen W
PROVIDER: S-EPMC4639830 | biostudies-literature | 2015 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA